Journal
NATURE REVIEWS CANCER
Volume 2, Issue 9, Pages 657-672Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc884
Keywords
-
Categories
Ask authors/readers for more resources
For more than two decades, the view that tumour-associated matrix metalloproteinases; (MMPs) were required for peritumour tissue degradation and metastasis dominated the drive to develop MMP inhibitors as anticancer therapeutics. Until recently, clinical trials with MMIP inhibitors have yielded disappointing results, highlighting the need for better insight into the mechanisms by which this growing family of multifunctional enzymes contribute to tumour growth. It is now recognized that MMP activity is tightly regulated at several levels, providing new avenues for blocking these enzymes. What are the different approaches that can be used to target MMPs, and which of these might lead to new therapeutic strategies for cancer?.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available